
Article

Not peer-reviewed version

17 β -Estradiol Effects in Skeletal Muscle: A 31P MR Spectroscopic Imaging (MRSI) Study of Young Females during Early- Follicular (EF) and Peri-ovulation (PO) Phases

[Jimin Ren](#) ^{*}, Luis Rodriguez, Talon Johnson, [Anke Henning](#) ^{*}, [Yasin Dhaher](#) ^{*}

Posted Date: 20 December 2023

doi: 10.20944/preprints202312.1584.v1

Keywords: phosphocreatine, estrogen, skeletal muscle, metabolism, magnesium, 31P MRS, 7T



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

17 β -Estradiol Effects in Skeletal Muscle: A ^{31}P MR Spectroscopic Imaging (MRSI) Study of Young Females during Early-Follicular (EF) and Peri-ovulation (PO) Phases

Jimin Ren ^{*1,2}, Luis Rodriguez ^{*3,4}, Talon Johnson ¹, Anke Henning, ^{1,2} and Yasin Dhaher ^{3,4}

¹ Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, United States

² Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, United States

³ Department of Bioengineering, University of Texas at Dallas, Richardson, TX, United States

⁴ Department of Physical Medicine and Rehabilitation, University of Texas Southwestern Medical Center, Dallas, TX, United States

Corresponding author contacts:

* Correspondence: Yasin Dhaher yasin.dhaher@utsouthwestern.edu; Anke Henning

anke.henning@utsouthwestern.edu; Jimin Ren Jimin.Ren@utsouthwestern.edu

JR and LR are equal contributors

Abstract: The natural variation in estrogen secretion throughout the female menstrual cycle impacts various organs, including estrogen receptor (ER)-expressed skeletal muscle. Many women commonly experience increased fatigue or reduced energy levels in the days leading up to and during menstruation when blood estrogen levels decline. Yet, it remains unclear whether endogenous 17 β -estradiol, a major estrogen component, directly affects energy metabolism in skeletal muscle due to the intricate and fluctuating nature of female hormones. In this study, we employed 3D ^{31}P FID-MRSI to investigate phosphoryl metabolites in the soleus muscle of a cohort of young females (average age: 28 ± 6 years, $n = 7$) during the early follicular (EF) and peri-ovulation (PO) phases when their blood 17 β -estradiol levels differ significantly (EF: 28 ± 18 pg/mL vs. PO: 71 ± 30 pg/mL, $p < 0.05$), while the levels of other potentially interfering hormones remain relatively invariant. Our findings reveal a reduction in ATP-referenced phosphocreatine (PCr) levels in the EF phase compared to the PO phase for all participants ($5.4 \pm 4.3\%$). Furthermore, we observe a linear correlation between muscle PCr levels and blood 17 β -estradiol concentrations ($r = 0.64$, $p = 0.014$). Conversely, inorganic phosphate Pi and phospholipid metabolite GPC levels remain independent of 17 β -estradiol but display a high correlation between EF and PO phases ($p = 0.015$ for Pi and $p = 0.0008$ for GPC). The robust association we have identified between ATP-referenced PCr and 17 β -estradiol suggests that 17 β -estradiol plays a modulatory role in the energy metabolism of skeletal muscle.

Keywords: phosphocreatine; estrogen; skeletal muscle; metabolism; magnesium; ^{31}P MRS; 7T

Introduction

The secretion of 17 β -estradiol, a key estrogen hormone, undergoes natural variations throughout the menstrual cycle in young women. These fluctuations, while integral to the female reproductive system, also exert significant influence over various organs, including the skeletal muscle, the largest in the human body (approximately 37 % in females). Several estrogen receptors (ER) have been found in skeletal muscle, including the membrane-bound GPER and nuclear-type ER- α/β , both activated upon binding with estrogen molecules (1-5). During or before menstruation, when blood estrogen levels decrease, many women frequently experience increased fatigue and diminished energy levels (6,7). Additionally, estrogen deficiency, often seen in menopausal women, has been linked to a range of musculoskeletal and neuromuscular disorders, such as sarcopenia, osteoporosis, frailty, obesity, dementia, atherosclerosis, metabolic syndrome, and type 2 diabetes, with reported benefits when endogenous estrogen levels rise or exogenous estrogen is supplemented (2,8-16).



Despite these observations, a comprehensive understanding of the effects of 17β -estradiol on energy metabolism in skeletal muscle remains elusive due to the complex and fluctuating nature of sex hormones throughout the menstrual cycle (4,14). In our study, we utilized advanced 3D 31P FID-MRSI (31-Phosphorus Magnetic Resonance Spectroscopic Imaging) to investigate alterations in phosphoryl metabolites within the soleus muscle of young females during two distinct menstrual phases: the early follicular (EF) and peri-ovulation (PO) phases. Importantly, these phases were selected for their significant disparities in blood 17β -estradiol levels, while other potentially interfering hormones, such as progesterone and parathyroid hormone (PTH), remained consistently low (14).

The soleus muscle was chosen as the focal point of our study due to its pivotal role in various weight-bearing activities, such as walking, running, and jumping, all of which are substantially affected by conditions like sarcopenia and osteoporosis (17,18). Both these prevalent musculoskeletal disorders share a common dysregulation pattern in females, marked by declining estrogen bioavailability (18-19). Metabolically, the soleus muscle, composed of approximately 78% type I fibers and well-perfused by blood, is considered to be fatigue-resistant and oxidative in energetics. Furthermore, its favorable volume-based shimming properties, including large size and inner location, make it particularly suitable for localized MRS studies. Consequently, the soleus muscle promises intrinsically high MRS detection sensitivity and spectral resolution, making it ideal option for capturing subtle metabolic changes resulting from hormonal fluctuations during the menstrual cycle.

Recent 31P MRS studies have hinted at the modulation of mitochondrial energy metabolism by gender and menopausal status, albeit primarily in the context of the brain, another organ rich in estrogen receptors (20-21). For instance, using 3T 31P MRSI, researchers found lower ATP-referenced phosphocreatine (PCr) levels in the brains of post-menopausal women compared to men (22). In animal models, estrogen withdrawal was observed to significantly increase the nucleoside ATP/Pi ratio in estrogen-dependent human breast cancer xenografts, while dietary creatine supplementation inhibited the growth of various tumors by increasing PCr levels without affecting ATP content (23-24). Remarkably, to the best of our knowledge, the impact of endogenous 17β -estradiol on PCr in skeletal muscle has not yet been explored using 31P MRSI techniques.

2. Materials and Methods

2.1. Cohort Characterization, Protocol Approvals, and Consent

This study was approved by the Institutional Review Board of The University of Texas Southwestern Medical Center. Seven healthy eumenorrheic females participated in the study, with no history of lower limb disorder, age 28 ± 6 years (range 21 – 38), BMI 25 ± 4 kg/m 2 , heart rate 68 ± 22 , and blood oxygen saturation 99 ± 1 %. Exclusion criteria included a history of musculoskeletal or orthopedic injury of the spine, hip, knee, ankle, or foot; history of neurological injury or disease of the peripheral or central nervous system; current smoking habit; history of disordered eating, stress fracture, connective tissue disorder (Marfan syndrome, Ehlers-Danlos disease), or menstrual dysfunction (primary or secondary amenorrhea, oligomenorrhea, anovulatory cycles, polycystic ovarian disease); current or prior pregnancy; use of an oral contraceptive within the previous 6 months; or use of an injectable or implantable contraceptive. All participants were scanned in both EF and PO phases according to their menstrual cycles. Informed and written consents were obtained from all subjects prior to MRI scans.

2.2. MRS Protocol

All subjects were positioned feet-first and supine in the MRI scanner (7T Achieva, Philips Healthcare, Best, the Netherlands), with calf muscle of the non-dominant leg positioned in the center of the RF coil (Philips Healthcare, Best, the Netherlands). The leg position was secured by Velcro straps with a thick pad in between for cushion, and the subject were asked to keep still and not to make muscle excursions during the scan. The RF coil was a half-cylinder-shaped partial volume,

double-tuned 1H/31P quadrature transmit/receive coil consisting of two tilted, partially overlapping 10-cm loops, with a solid base that can be firmly attached to the scanner table. Axial and sagittal T2-weighted turbo spin echo images were acquired for planning the 1H-based Bo shimming (by second order pencil-beam projection method, with shimming volume located in the soleus muscle) and the 31P MRSI acquisition data matrix.

31P MR spectra were acquired with a 2D FID-MRSI sequence using a block pulse at TR 1.0 s, TE 0.48 ms, B1 59 μ T, flip angle 55°, effective excitation bandwidth 3.2 kHz, receiver bandwidth 8 KHz, in-plane resolution of 8×7.5 mm², k-space acquisition weighting ($\alpha = 1.7$ and $\beta = 1.0$), elliptic k-space sampling with 4 k points zero-filled to 8 k prior to Fourier transformation, data matrix (RL x AP) = 12 x 6 reconstructed to 15 x 8, field-of-view FOV (RL x AP) = 120 x 60 mm², nominal slice thickness 30 cm, number of average NA = 16, and scan time 7 min. A non-localized fully-relaxed 31P spectrum was also acquired from each subject with pulse-acquire sequence at TR = 25 s and NA = 8.

2.3. Data Analysis

The time-domain ³¹P FID data were post-processed (zero-filling, apodization, Fourier transformation, and zero- and first-order phasing) using the scanner software (SpectroView, Philips Healthcare). Frequency-domain ³¹P spectra from selected soleus voxels within the shimming volume were summed after individually aligned to PCr at 0 ppm, and then analyzed by lineshape fitting using an in-house program written in Matlab (MathWorks, Natick, MA, USA).²⁵⁻²⁷ Typically all 31P peaks of interest were fitted by a single Gaussian lineshape model except Pi, which is deconvoluted into extra- and intracellular components(Pi(ex) and Pi(in)), and the mixed signal in -7.5 – -9.5 ppm, which is deconvoluted into a-ATP and NAD, using two Gaussian lineshapes at different chemical shifts. Prior-knowledge of peak chemical shifts was included as soft constraints²⁵. The PCr map representing an interpolation to the same resolution as the T2-weighted image was generated using SpectroView by bilinear interpolation from the nearest voxels. Voxel-summed 31P MR spectra were obtained respectively for the EF and PO phases over all subjects (n = 7). All signals were normalized with respect to γ -ATP in integral, without T1 correction for partial saturation effect.

2.4. Evaluation of Intracellular pH

The intracellular pH was evaluated from the chemical shift of the Pi resonance (δ_{Pi}) according to the Henderson–Hasselbalch equation as published previously:²¹

$$pH = pK_a + \log_{10}[(\delta_{Pi} - \delta_a) / (\delta_b - \delta_{Pi})] \quad \text{Eq.[1]}$$

where the reaction $H_2PO_4^- \leftrightarrow H^+ + HPO_4^{2-}$ deprotonation constant $pK_a = 6.73$ and the ³¹P limiting shifts $\delta_a = 3.275$ ppm (for the acidic protonated species $H_2PO_4^-$) and $\delta_b = 5.685$ ppm (for the basic deprotonated species HPO_4^{2-}) were used in the data analysis.

2.5. Evaluation of Intracellular Mg²⁺

The intracellular free Mg²⁺ concentration was evaluated from the chemical shift of β -ATP resonance (δ_{β}) according to the following equation:

$$[Mg^{2+}] = k_d (\delta_{\beta} - \delta_{ATP}) / (\delta_{MgATP} - \delta_{\beta}) \quad \text{Eq.[2]}$$

where the reaction $MgATP \leftrightarrow Mg^{2+} + ATP$ disassociation constant $k_d = 0.05$ mM (or $pK_d = 4.30$) and the limiting shifts $\delta_{MgATP} = -15.74$ ppm (for the 1:1 complex MgATP) and $\delta_{ATP} = -18.58$ ppm (for the free ATP species) were used in the data analysis.

2.6. Analysis of 17 β -Estradiol

Circulating 17 β -estradiol concentrations were measured in serum. Briefly, venipuncture was performed at the antecubital area of the arm. Whole blood was collected with a red top, vacutainer serum collection tube (Becton Dickinson, Franklin Lakes, NJ), processed according to the manufacturer's recommendations, aliquoted, and stored at -80°C for future analysis. Frozen serum samples were then sent to a clinical laboratory service (Medfusion, Lewisville, TX) to confirm the self-reported menstrual cycle phase of the subject.

2.7. Statistical Analysis

Data reported as mean \pm standard deviation, and a p-value ≤ 0.05 is statistically significance.

3. Results

3.1. Voxel 31P MRSI Spectra

The 7T 31P MRSI spectra acquired from selected soleus voxels exhibited excellent spectral resolution and SNR, as evident in spectra from individual subjects (Figures 1A) and the cohort-summed spectrum (Figure 1B). High-intensity, well-defined signals include Pi(in), GPC, PCr, α -, β -, and γ -ATP, which can be easily detected from single voxels (Figures 1C and 1D). Low-intensity signals that can be reliably measured only in voxel-summed spectra include Pi(ex), GPE, PME (a composite of various metabolites primarily constituted of sugar phosphates), and NAD (a mixture of both oxidized and reduced forms). Notably, among these measurable metabolites, PCr exhibited the highest detection sensitivity, and its distribution across the axial plane could be spatially mapped (Figure 1E). Table 1 summarizes the chemical shifts and ATP-reference signal intensities for all measureable 31P peaks in the soleus muscle at rest.

Table 1. 31P MRS measurements of PCr-to-ATP ratio (by integral), intracellular pH and free [Mg²⁺] (mM) in soleus muscle of young females (n = 7).

	δ	(ppm)		PCr/ATP	(a.u.)	PO
PME	6.63	± 0.21	0.10	± 0.04	0.07	± 0.03
Pi(ex)	5.14	± 0.06	0.06	± 0.03	0.05	± 0.02
Pi(in)	4.81	± 0.02	0.30	± 0.08	0.31	± 0.09
GPE	3.51	± 0.04	0.03	± 0.01	0.03	± 0.01
GPC	2.97	± 0.01	0.19	± 0.10	0.20	± 0.10
PCr	[0]		3.82	± 0.18	4.05	$\pm 0.18^*$
γ -ATP	-2.41	± 0.01	[1.0]		[1.0]	
α -ATP	-7.48	± 0.02	1.08	± 0.08	1.09	± 0.08
NAD	-8.06	± 0.10	0.27	± 0.05	0.33	± 0.14
β -ATP	-15.95	± 0.03	1.16	± 0.07	1.25	± 0.08
pH			6.983	± 0.014	6.990	± 0.018
Mg (mM)			0.68	± 0.08	0.60	± 0.08

Note: Data measured with 2D ³¹P MRSI at 7T under conditions of TR = 1 s and TE = 0.5 ms using a partial volume T/R RF coil; PCr used as an endogenous reference for chemical shift at 0 ppm and γ -ATP as a reference for signal intensity (integral). Gaussian lineshape deconvolution performed between intra- and extracellular Pi and between α -ATP and NAD. Signal intensity reported without correction for partial saturation. * p < 0.05.

Figure 1. (A) 7T 31P spectra acquired by 2D MRSI from soleus muscle in seven females. (B) Group-summed 31P spectrum. (C) 2D 31P MRSI matrix showing the placement of voxels (red) and shimming box (green) over an axial T2w MR image. (D) Screenshot of voxels 31P spectra in the soleus region of interest (yellow matrix, C). (E) PCr color map reconstructed from voxel 31P spectra.

3.2. EF and PO Difference in 31P Spectra

Figure 2 compares the group-averaged 31P spectra acquired during the EF and PO phases. A notable difference is evident in the PCr signal, which exhibited a 6% of decrease in the EF phase (red trace), as compared to PO phase (blue trace, top, Figure 2). Additionally, a downfield peak shift was observed at β -ATP (by 0.02 ppm), indicative of a higher free Mg concentration (0.06 mM) in the EF phase relative to PO phase. In contrast, intracellular pH remained remarkably similar between these two phases (Δ pH < 0.01 unit), as evidenced by the negligible change in chemical shift at Pi(in) (0.006

ppm). No significant difference was detected for the low-magnitude signals PME, Pi(ex), GPE and NAD.

Figure 2. Comparison of group-averaged voxel 31P MR spectra acquired from soleus muscle during EF (red) and PO (blue) phases ($n = 7$). Insets: Enlarged signals showing EF and PO difference in PCr signal intensity (top) and β -ATP chemical shift (bottom). No EF and PO difference seen in chemical shift at Pi with respect to PCr (at 0 ppm). .

Figure 3 represents individual measurement results for the EF and PO phases. The decline in PCr during the EF phase compared to the PO phase was consistent across all seven participants, ranging from 1.5% to 13.5% (averaging $5.4 \pm 4.3\%$, Figure 3A). In five out of the seven subjects, a higher cytosolic free Mg concentration was observed during the EF phase compared to the PO phase, with a group-average of 0.68 ± 0.08 mM in the EF phase versus 0.60 ± 0.08 mM in the PO phase (Figure 3B). The pH levels exhibited minimal variation between these two phases, averaging 6.983 ± 0.014 in the EF phase and 6.990 ± 0.018 in the PO phase (Figure 3C).

Figure 3. Comparison between EF and PO in PCr 31P signal intensities (A), free Mg^{2+} concentrations (B), and pH for individuals. .

3.3. EF and PO Difference in 17 β -Estradiol

Serum measurements confirmed a substantial decrease in 17 β -estrogen concentration during the EF phase compared to the PO phase (28 ± 18 vs. 71 ± 30 pg/mL, $p = 0.021$). Notably, the levels of serum 17 β -estrogen displayed considerable heterogeneity among individuals within this cohort, ranging from less than 10 to 62 pg/mL during the EF phase and from 36 to 116 pg/mL during the PO phase. This wide range of values allows for a more comprehensive exploration of the dependence on 17 β -estrogen.

3.4. Correlation between Blood 17 β -Estrogen and Soleus 31P Signals

Table 2 summarizes results of the of linear correlation analysis. A significant linear correlation was found between blood 17 β -estrogen levels and muscle PCr signal intensities ($r = 0.638$, $p = 0.014$, Figure 4A). Notably, the ATP-referenced PCr signal exhibited a tendency to increase with rising 17 β -estrogen levels (with an intercept of 3.746 and a slope of 0.004). Conversely, an inverse trend was observed for intracellular free Mg (Figure 4B); however, this correlation did not attain statistical significance ($r = -0.304$, $p = 0.290$). Importantly, no significant correlation was detected between blood 17 β -estrogen levels and muscle intracellular pH (Figure 4C).

Table 2. Results of linear correlation between 17 β -estradiol and PCr.

metabolites	p-value	r-value
PME	0.951	-0.018
Pi(ex)	0.985	-0.005
Pi(in)	0.332	0.280
GPE	0.625	-0.143
GPC	0.766	0.088
PCr	0.014	0.638
γ -ATP	-	-
α -ATP	0.295	0.301
NAD	0.458	-0.216
β -ATP	0.158	0.398
pH	0.910	0.033
Mg	0.290	-0.304

Note. 17 β -estradiol levels (pg/mL) measured in serum, PCr signal intensities measured from soleus in reference to γ -ATP by integral; intracellular pH measured from Pi(in) chemical shift with respect to PCr by Equation [1], and free Mg^{2+} concentration (in mM) measured from β -ATP chemical shift by Equation [2]. .

Figure 4. Linear correlation of the blood 17 β -estradiol concentrations with PCr 31P signal intensities (A, $r = 0.64$, $p = 0.014$), free Mg²⁺ concentrations (B, $r = -0.30$, $p = 0.29$), and pH (C, $r = 0.03$, $p = 0.91$) for individual subjects in EF and PO phases. Solid lines showing the fitted data and dashed lines showing ± 1 unit of standard deviation.

3.5. Metabolite Correlation between EF and PO Phases

Within this subject cohort, the 31P signal intensities of GPC and Pi(in) (Figure 1A) exhibited a broad range of values (Figure 5). A robust linear correlation with an almost unity slope was evident for both GPC ($r = 0.956$, $p = 0.0008$) and Pi(in) ($r = 0.850$, $p = 0.015$) when comparing the EF and PO phases (Figures 5A and 5B). However, neither GPC nor Pi(in) displayed a linear correlation with 17 β -estradiol levels (Figures 5C and 5D). Instead, it appears that body mass index (BMI) emerges as a noteworthy factor influencing GPC variations among individuals, as indicated by the results of linear correlation analysis ($r = 0.708$, $p = 0.075$). BMI also appears to affect on inorganic phosphates, with correlations of $r = 0.632$ ($p = 0.127$) for Pi(in) and $r = 0.679$ ($p = 0.093$) for Pi(ex).

Figure 5. Linear correlation of EF and PO data in 31P signal intensities of GPC (A, $r = 0.956$, $p = 0.0008$) and Pi(in) (B, $r = 0.850$, $p = 0.015$). Linear correlation of blood 17 β -estradiol levels with 31P signal intensities of GPC (C, $r = 0.088$, $p = 0.766$) and Pi(in) (D, $r = 0.280$, $p = 0.332$). Note that the strong signal correlations between EF and PO in GPC and Pi(in) 31P signals (A and B) when these signals appear to be independent of 17 β -estradiol. .

4. Discussion

4.1. Major Findings

To the best of our knowledge, this study represents the first quantitative investigation into the influence of the sex hormone 17 β -estradiol on energy metabolism within the soleus muscle, utilizing localized 31P MRSI. The results demonstrated a significant linear correlation between the high-energy metabolite PCr and blood 17 β -estradiol levels in young females. Particularly, the γ -ATP-referenced PCr levels within the soleus muscle exhibit a decline during the low-17 β -estradiol EF phase in contrast to the high-17 β -estradiol PO phase. This finding suggests a potential role for 17 β -estradiol in influencing the energy metabolism of skeletal muscle.

4.2. Role of PCr in Energy Metabolism

PCr, serving as the immediate buffer for the universal bioenergy currency ATP, is notably abundant in skeletal muscle. This abundance extends to both its overall quantity, considering that skeletal muscle comprises approximately 30-35% of the female body mass, and its PCr-to-ATP ratio, which is notably higher in skeletal muscle (~4.0 (26)) compared to other tissues such as the heart (~2.0 (29, 30)), brain (~1.5 (25, 27)), kidney and male prostate (~1.0, (31-34)), and liver (< 0.2 (35)). These characteristics underscore the pivotal role of PCr in maintaining energy homeostasis within skeletal muscle, particularly in responding to rapidly fluctuating energy demands.

A heightened PCr store implies an increased capacity for ATP buffering, facilitated by the creatine kinase (CK) reaction. A decline in PCr levels may negatively affect muscle performance, thus contributing to the fatigue and physical stress commonly associated with menstrual and premenstrual syndromes. Conversely, the finding of elevated PCr levels during the PO phase compared to the EF phase aligns with the idea that rising estrogen levels, whether endogenously or through replacement therapy, could enhance physical energy and improve productivity for many females throughout their reproductive and postmenopausal stages (36).

Indeed, the impacts of a deficiency in CK substrates on physiological function are well-documented. Conditions like brain creatine deficiency syndrome have been established to be associated with epilepsy and movement disorders (37-39). Additionally, CK substrate deficiency can exert adverse effects on mitochondrial function, particularly within the context of energy production in skeletal muscle (40).

In cytosolic CK knockout mice, a reduced breakdown in PCr to support ATP regeneration was found to be associated with a delayed muscle relaxation after repeated muscle contractions (41).

4.3. Correlation between PCr and 17β -Estradiol

The increased PCr in the soleus muscle in the PO phase relative to EF phase was attributed to the effect of increasing 17β -estradiol concentrations in the blood (Figures 3 and 4A), as suggested by the linear correlation between these two measurements ($p < 0.05$, Figure 5A). We excluded the possibility that the observed PCr change from EF to PO phase is due to prior exercise or incident muscle excursion during the scan, given that all subjects in this cohort were well screened for physical exercise 48 hrs prior to MRI visit and remained at rest during scan with continuous monitoring. High detection sensitivity and spectral resolution at 7T is a key factor in revealing small changes. A previous 31P MRS study reported an observation of change in brain high-energy metabolites upon visual stimulation (42), though another study at 3T did not see significant change at the detection threshold in the brain (~5%) (43)). It should be noted that PCr detection sensitivity is about one order of magnitude higher in skeletal muscle than in brain under comparable conditions, mainly due to PCr's intrinsically higher concentrations in the skeletal muscle (approximately 35 mM) than in the brain (approximately 3.5 mM).

4.4. Acting Sites of 17β -Estradiol

17β -estradiol, as a hydrophobic steroid hormone, is unlikely engaged in direct chemical interactions with water-soluble energy metabolites in the cytosol. However, its influence on the energy system may result from its binding to receptors located in various cellular compartments, including the nucleus (where the majority of ERs are concentrated), mitochondria, and the cell membrane (comprising a smaller pool of ER α and ER β receptors, ~5-10%) (44). Dysregulation of this estrogen signaling system has been proposed as a potential trigger for pathologies such as Alzheimer's disease in post-menopausal women (45). Notably, this neurodegenerative condition is associated with a decrease in ATP-referenced PCr levels (46), aligning well with our findings of lower PCr levels during the low- 17β -estradiol early follicular phase compared to the high- 17β -estradiol peri-ovulation phase (Figure 3A).

4.5. Membrane Phospholipids (MPL) Metabolites

Considering the established role of estrogen in preserving cell membrane integrity and reducing oxidative damage (47), it is reasonable to speculate that elevated 17β -estradiol levels might lead to a decrease in the cytosolic products from the degradation of membrane phospholipids (MPL). In the current 31P study, GPC is the sole MPL degradation metabolite with sufficient abundance for reliable measurement (Figure 1A). While GPC levels do display considerable variability among individual subjects and remain highly consistent between two separate visits during both EF and PO phases (Figure 5A), we did not observe any correlation between GPC levels and serum 17β -estradiol levels (Figure 5C).

These findings suggest that the anticipated protective role of 17β -estradiol against membrane oxidation damage does not result in measurable changes in the cleavage of hydrophilic phospholipid head groups in association with cytosolic GPC accumulation. Instead, its protection on membrane integrity may result from its hydrophobic interaction with the fatty acid moiety of MPLs, presumably through the membrane-bound receptors ER α and ER β located in lipid rafts (44),

4.6. pH and Free Mg Measurements

Our investigation did not yield evidence of 17β -estradiol-dependent changes in cellular pH between the EF and PO phases (Figures 3C and 4C). Nevertheless, it's noteworthy that in the majority of the subjects studied (5 out of 7), a higher concentration of free Mg $^{2+}$ was observed in the EF phase compared to the PO phase (Figure 3B). While this trend appears to be influenced by 17β -estradiol levels, it is not notably strong (Figure 4B) as seen at PCr (Figure 4A).

The role of Mg²⁺ as an essential cofactor in enzymatic ATP hydrolysis activation highlights its critical importance in the realm of energy metabolism and muscle function (48). Maintaining adequate levels of Mg²⁺ has long been recognized as crucial in the prevention of fatigue and the alleviation of muscle cramps and spasms, issues commonly encountered not only by endurance athletes but also by females dealing with menstrual syndromes (49,50). Furthermore, it's noteworthy that natural postmenopausal women typically exhibit lower serum estrogen levels in conjunction with higher magnesium levels when compared to healthy premenopausal women (51). Additionally, estrogen supplementation has been shown to reduce the hypermagnesuria observed in postmenopausal women (52). Elevated muscle magnesium levels have also been frequently documented in chronic fatigue syndrome (53), a condition that primarily affects middle-aged individuals and is four times more prevalent in women than in men (54).

Our current study aligns with these previous findings by demonstrating higher Mg²⁺ levels in the low-17 β -estradiol EF phase relative to the high-17 β -estradiol PO phase (Figure 3B). Taken together, these results provide compelling evidence for a potential interplay between 17 β -estradiol regulation and magnesium metabolism, which may involve complex interactions among bone, kidney, and skeletal muscle (36,55). Further research is needed to explore and elucidate the intricate relationships between these factors and their implications for overall health and well-being.

A limitation of this preliminary study is its small cohort size, consisting of only seven participants, which may limit the generalizability of the findings. Further research with a larger cohort is necessary to validate these results. Additionally, it would be beneficial to broaden the scope of the study to include the investigation of other hormones, such as progesterone, which is notably elevated during the luteal phase of the late menstrual cycle. Additionally, it would be interesting to explore how and to what extent endogenous 17 β -estradiol affects the more glycolytic gastrocnemius muscle as compared to the more oxidative soleus muscle.

In conclusion, using localized 7T 31P MRSI, our study has revealed a decline in ATP-referenced PCr levels during the low-17 β -estradiol early follicular phase compared to the high-17 β -estradiol peri-ovulation phase. Furthermore, we have demonstrated a significant linear correlation between the ATP-referenced PCr levels in the soleus muscle and the circulating blood concentrations of 17 β -estradiol. These findings provide *in vivo* evidence supporting the additional role of 17 β -estradiol in modulating the energy metabolism of skeletal muscle. These insights may have clinical significance in the management of symptoms associated with estrogen deficiency in females. Furthermore, our work highlights the need for further research with larger cohorts and a broader scope to fully elucidate the complex interplay of hormones and energy metabolism in skeletal muscle.

Acknowledgements: The authors are grateful for Corey Mozingo for 7T operational assistance.

Funding Statement: University of Texas Southwestern Medical Center

Abbreviations used:

- ADP, adenosine diphosphate
- BMS, bulk magnetic susceptibility effect
- Cr, free creatine
- EF, Early Follicular
- ER, estrogen receptors
- GPC, glycerolphosphocholine
- GPE, glycerolphosphoethanolamine
- HF, header-foot
- MPL, membrane phospholipids
- NAD, nicotinamide adenine dinucleotide, a combination of the oxidized form NAD⁺ and the reduced form NADH
- NTP, nucleoside triphosphates,
- PCr, phosphocreatine
- PC, phosphocholine

PE, phosphoethanolamine
Pi, inorganic phosphate
PDE, phosphodiester
PME, phosphomonoester
PO, peri-ovulation
PTH, parathyroid hormone

References

1. Xia H, Scholtes C, Dufour CR, Guluzian C, Giguère V. *ERR α fosters running endurance by driving myofiber aerobic transformation and fuel efficiency*. *Mol Metab*. 2023;101814.
2. Yoh K, Ikeda K, Horie K, Inoue S. *Roles of Estrogen, Estrogen Receptors, and Estrogen-Related Receptors in Skeletal Muscle: Regulation of Mitochondrial Function*. *Int J Mol Sci*. 2023;24(3):1853.
3. Wiik A, Ekman M, Johansson O, Jansson E, Esbjörnsson M. *Expression of both oestrogen receptor alpha and beta in human skeletal muscle tissue*. *Histochem Cell Biol*. 2009;131(2):181-9.
4. Ekenros L, Papoutsi Z, Fridén C, Dahlman Wright K, Lindén Hirschberg A. *Expression of sex steroid hormone receptors in human skeletal muscle during the menstrual cycle*. *Acta Physiol (Oxf)*. 2017;219(2):486-493.
5. Wiik A, Glenmark B, Ekman M, Esbjörnsson-Liljedahl M, Johansson O, Bodin K, Enmark E, Jansson E. *Oestrogen receptor beta is expressed in adult human skeletal muscle both at the mRNA and protein level*. *Acta Physiol Scand*. 2003;179(4):381-7.
6. Lin G, Siddiqui R, Lin Z, Blodgett JM, Patel SN, Truong KN, Mariakakis A. *Blood glucose variance measured by continuous glucose monitors across the menstrual cycle*. *NPJ Digit Med*. 2023;6(1):140.
7. Alshdaifat E, Absy N, Sindiani A, AlOsta N, Hijazi H, Amarin Z, Alnazly E. *Premenstrual Syndrome and Its Association with Perceived Stress: The Experience of Medical Students in Jordan*. *Int J Womens Health*. 2022;14:777-785.
8. Geraci, A.; Calvani, R.; Ferri, E.; Marzetti, E.; Arosio, B.; Cesari, M. *Sarcopenia and Menopause: The Role of Estradiol*. *Front. Endocrinol. (Lausanne)* 2021, 12, 682012.
9. De Paoli M, Zakharia A, Werstuck GH. *The role of estrogen in insulin resistance: a review of clinical and preclinical data*. *Am J Pathol* 2021; 191:1490-8.
10. Writing Group for the Women's Health Initiative Investigators. *Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial*. *JAMA*. 2002;288(3):321-33.
11. Sipilä, S.; Törmäkangas, T.; Sillanpää, E.; Aukee, P.; Kujala, U.M.; Kovanen, V.; Laakkonen, E.K. *Muscle and Bone Mass in Middle-Aged Women: Role of Menopausal Status and Physical Activity*. *J. Cachexia Sarcopenia Muscle* 2020, 11, 698-709.
12. Tashjian RZ, Zitnay J, Kazmers NH, Veerabhadraiah SR, Zelada AC, Honegger M, Chalmers PN, Henninger HB, Juryneć MJ. *Estrogen and testosterone supplementation improves tendon healing and functional recovery after rotator cuff repair*. *J Orthop Res*. 2023 Sep 27. doi: 10.1002/jor.25695. Online ahead of print.
13. Mitoma T, Maki J, Ooba H, Eto E, Takahashi K, Kondo T, Ikeda T, Sakamoto Y, Mitsuhashi T, Masuyama H. *Protocol for a randomised, placebo-controlled, double-blinded clinical trial on the effect of oestrogen replacement on physical performance to muscle resistance exercise for older women with osteoarthritis of knee joint: the EPOK trial*. *BMC Geriatr*. 2023;23(1):104.
14. Unger CA, Aladhami AK, Hope MC, Cotham WE, Nettles KW, Clegg DJ, Velázquez KT, Enos RT. *Skeletal Muscle Endogenous Estrogen Production Ameliorates the Metabolic Consequences of a High-Fat Diet in Male Mice*. *Endocrinology*. 2023;164(8):bqad105.
15. Samad N, Nguyen HH, Hashimura H, Pasco J, Kotowicz M, Strauss BJ, Ebeling PR, Milat F, Vincent AJ. *Abnormal Trabecular Bone Score, Lower Bone Mineral Density and Lean Mass in Young Women With Premature Ovarian Insufficiency Are Prevented by Oestrogen Replacement*. *Front Endocrinol (Lausanne)*. 2022;13:860853.
16. Chidi-Ogbolu N, Baar K. *Effect of Estrogen on Musculoskeletal Performance and Injury Risk*. *Front Physiol*. 2019;9:1834.
17. Reginster JY, Beaudart C, Buckinx F, Bruyère O. *Osteoporosis and sarcopenia: two diseases or one?* *Curr Opin Clin Nutr Metab Care*. 2016;19(1):31-6.
18. Tagliaferri C, Wittrant Y, Davicco MJ, Walrand S, Coxam V. *Muscle and bone, two interconnected tissues*. *Ageing Res Rev*. 2015;21:55-70.
19. Armstrong VJ, Muzyłak M, Sunters A, Zaman G, Saxon LK, Price JS, Lanyon LE. *Wnt/beta-catenin signaling is a component of osteoblastic bone cell early responses to load-bearing and requires estrogen receptor alpha*. *J Biol Chem*. 2007;282(28):20715-27.

20. Mosconi L, Berti V, Dyke J, Schelbaum E, Jett S, Loughlin L, Jang G, Rahman A, Hristov H, Pahlajani S, Andrews R, Matthews D, Etingin O, Ganzer C, de Leon M, Isaacson R, Brinton RD. Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition. *Sci Rep.* 2021;11(1):10867.
21. Mosconi L, Jett S, Nerattini M, Andy C, Yepez CB, Zarate C, Carlton C, Kodancha V, Schelbaum E, Williams S, Pahlajani S, Loeb-Zeitlin S, Havryliuk Y, Andrews R, Pupi A, Ballon D, Kelly J, Osborne J, Nehmeh S, Fink M, Berti V, Matthews D, Dyke J, Brinton RD. In vivo Brain Estrogen Receptor Expression By Neuroendocrine Aging And Relationships With Gray Matter Volume, Bio-Energetics, and Clinical Symptomatology. *Res Sq.* 2023 Feb 27:rs.3.rs-2573335. doi: 10.21203/rs.3.rs-2573335/v1. Preprint.
22. Jett S, Dyke JP, Andy C, Schelbaum E, Jang G, Boneu Yepez C, Pahlajani S, Diaz I, Diaz Brinton R, Mosconi L. Sex and menopause impact 31P-Magnetic Resonance Spectroscopy brain mitochondrial function in association with 11C-PiB PET amyloid-beta load. *Sci Rep.* 2022;12(1):22087.
23. Kristensen CA, Kristjansen PE, Brünner N, Clarke R, Spang-Thomsen M, Quistorff B. Effect of estrogen withdrawal on energy-rich phosphates and prediction of estrogen dependence monitored by in vivo 31P magnetic resonance spectroscopy of four human breast cancer xenografts. *Cancer Res.* 1995;55(8):1664-9.
24. Kristensen CA, Askenasy N, Jain RK, Koretsky AP. Creatine and cyclocreatine treatment of human colon adenocarcinoma xenografts: 31P and 1H magnetic resonance spectroscopic studies. *Br J Cancer.* 1999;79(2):278-85.
25. Ren J, Sherry AD, Malloy CR. (31)P-MRS of healthy human brain: ATP synthesis, metabolite concentrations, pH, and T1 relaxation times. *NMR Biomed.* 2015;28(11):1455-62.
26. Ren J, Sherry AD, Malloy CR. Modular 31 P wideband inversion transfer for integrative analysis of adenosine triphosphate metabolism, T1 relaxation and molecular dynamics in skeletal muscle at 7T. *Magn Reson Med.* 2019;81(6):3440-3452.
27. Ren J, Yu F, Greenberg BM. ATP line splitting in association with reduced intracellular magnesium and pH: a brain 31 P MR spectroscopic imaging (MRSI) study of pediatric patients with myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGADs). *NMR Biomed.* 2023;36(2):e4836.
28. Soedirdjo SDH, Rodriguez LA 2nd, Chung YC, Casey E, Dhaher YY. Sex hormone-mediated change on muscle activation deactivation dynamics in young eumenorrheic women. *Front Physiol.* 2023;14:1104578.
29. Ellis J, Valkovič L, Purvis LAB, Clarke WT, Rodgers CT. Reproducibility of human cardiac phosphorus MRS (31 P-MRS) at 7 T. *NMR Biomed.* 2019;32(6):e4095.
30. Niendorf T, Paul K, Oezerdem C, Graessl A, Klix S, Huelnhagen T, Hezel F, Rieger J, Waiczies H, Frahm J, Nagel AM, Oberacker E, Winter L. W(h)ither human cardiac and body magnetic resonance at ultrahigh fields? technical advances, practical considerations, applications, and clinical opportunities. *NMR Biomed.* 2016;29(9):1173-97.
31. Matson GB, Twieg DB, Karczmar GS, Lawry TJ, Gober JR, Valenza M, Boska MD, Weiner MW. Application of image-guided surface coil P-31 MR spectroscopy to human liver, heart, and kidney. *Radiology.* 1988;169(2):541-7.
32. Boska MD, Meyerhoff DJ, Twieg DB, Karczmar GS, Matson GB, Weiner MW. Image-guided 31P magnetic resonance spectroscopy of normal and transplanted human kidneys. *Kidney Int.* 1990;38(2):294-300.
33. Lagemaat MW, Maas MC, Vos EK, Bitz AK, Orzada S, Weiland E, van Uden MJ, Kobus T, Heerschap A, Scheenen TW. (31) P MR spectroscopic imaging of the human prostate at 7 T: T1 relaxation times, Nuclear Overhauser Effect, and spectral characterization. *Magn Reson Med.* 2015;73(3):909-20.
34. Kobus T, Bitz AK, van Uden MJ, Lagemaat MW, Rothgang E, Orzada S, Heerschap A, Scheenen TW. In vivo 31P MR spectroscopic imaging of the human prostate at 7 T: safety and feasibility. *Magn Reson Med.* 2012;68(6):1683-95. Male prostate PCr/ATP
35. Rata M, Giles SL, deSouza NM, Leach MO, Payne GS. Comparison of three reference methods for the measurement of intracellular pH using 31P MRS in healthy volunteers and patients with lymphoma. *NMR Biomed.* 2014;27(2):158-62.
36. Chidi-Ogbolu N, Baar K. Effect of Estrogen on Musculoskeletal Performance and Injury Risk. *Front Physiol.* 2019;9:1834.
37. Jonquel-Chevalier Curt M, Voicu PM, Fontaine M, Dessein AF, Porchet N, Mention-Mulliez K, Dobbelaere D, Soto-Ares G, Cheillan D, Vamecq J. Creatine biosynthesis and transport in health and disease. *Biochimie.* 2015;119:146-65.
38. Schulze A. Creatine deficiency syndromes. *Handb Clin Neurol.* 2013;113:1837-43.
39. Haas D, Gan-Schreier H, Langhans CD, Anninos A, Haege G, Burgard P, Schulze A, Hoffmann GF, Okun JG. Diagnosis and therapeutic monitoring of inborn errors of creatine metabolism and transport using liquid chromatography-tandem mass spectrometry in urine, plasma and CSF. *Gene.* 2014;538(1):188-94.
40. van den Broek NM, Ciapaite J, Nicolay K, Prompers JJ. Comparison of in vivo postexercise phosphocreatine recovery and resting ATP synthesis flux for the assessment of skeletal muscle mitochondrial function. *Am J Physiol Cell Physiol.* 2010;299(5):C1136-43.

41. Kan HE, Veltien A, Arnts H, Nabuurs CI, Luijten B, de Haan A, Wieringa B, Heerschap A. Gated dynamic 31P MRS shows reduced contractile phosphocreatine breakdown in mice deficient in cytosolic creatine kinase and adenylyl kinase. *NMR Biomed.* 2009;22(5):523-31.
42. Hendriks AD, van der Kemp WJM, Luijten PR, Petridou N, Klomp DWJ. SNR optimized 31 P functional MRS to detect mitochondrial and extracellular pH change during visual stimulation. *NMR Biomed.* 2019;32(11):e4137.
43. van de Bank BL, Maas MC, Bains LJ, Heerschap A, Scheenen TWJ. Is visual activation associated with changes in cerebral high-energy phosphate levels? *Brain Struct Funct.* 2018;223(6):2721-2731.
44. Wnuk A, Przepiórka K, Pietrzak BA, Kajta M. Emerging Evidence on Membrane Estrogen Receptors as Novel Therapeutic Targets for Central Nervous System Pathologies. *Int J Mol Sci.* 2023;24(4):4043.
45. Marin R; Canerina-Amaro A, Hernandez-Abad LG, Ferrer I, Quinto-Alemany D, Mesa-Herrera F, Ferri C, Puertas-Avendaño RA, Diaz M. Lipid raft ER signalosome malfunctions in menopause and Alzheimer's disease. *Front. Biosci.* 2017;9:111-126.
46. Das N, Ren J, Spence J, Chapman SB. Phosphate Brain Energy Metabolism and Cognition in Alzheimer's Disease: A Spectroscopy Study Using Whole-Brain Volume-Coil 31Phosphorus Magnetic Resonance Spectroscopy at 7Tesla. *Front Neurosci.* 2021;15:641739.
47. Moolman JA. Unravelling the cardioprotective mechanism of action of estrogens. *Cardiovasc Res.* 2006;69(4):777-80.
48. Iotti S, Frassineti C, Alderighi L, Sabatini A, Vacca A, Barbiroli B. In vivo (31)P-MRS assessment of cytosolic [Mg(2+)] in the human skeletal muscle in different metabolic conditions.
49. Magn Reson Imaging. 2000 Jun;18(5):607-14 Vitale K, Getzin A. Nutrition and Supplement Update for the Endurance Athlete: Review and Recommendations. *Nutrients.* 2019;11(6):1289.
50. Porri D, Biesalski HK, Limitone A, Bertuzzo L, Cena H, Effect of magnesium supplementation on women's health and well-being. *NFS Journal,* 2021;23:30-36.
51. Sonu Y, Avinash SS, Sreekantha, Arun Kumar K, Malathi M, Shivashankara AR. Effect of Oestrogen on Altering the Serum and Urinary Levels of Calcium, Phosphate and Magnesium in Hysterectomised Women Compared to Natural Menopausal South Indian Women: A Case Control Study. *Indian J Clin Biochem.* 2016;31(3):326-31.
52. McNair P, Christiansen C, Transbøl I. Effect of menopause and estrogen substitutional therapy on magnesium metabolism. *Miner Electrolyte Metab.* 1984;10(2):84-7.
53. McCully KK, Malucelli E, Iotti S. Increase of free Mg²⁺ in the skeletal muscle of chronic fatigue syndrome patients. *Dyn Med.* 2006;5:1.
54. <https://www.hopkinsmedicine.org/health/conditions-and-diseases/chronic-fatigue-syndrome>. Chronic Fatigue Syndrome, last retrieved Dec 4, 2023.
55. Blaine J, Chonchol M, Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. *Clin J Am Soc Nephrol.* 2015;10(7):1257-72.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.